Boron has been suggested to enhance the biological effectiveness of proton beams in the Bragg peak region via the p + 11B → 3α nuclear capture reaction. However, a number of groups have observed no such enhancement in vitro or questioned its proposed mechanism recently. To help elucidate this phenomenon, we irradiated DU145 prostate cancer or U-87 MG glioblastoma cells by clinical 190 MeV proton beams in plateau or Bragg peak regions with or without 10B or 11B isotopes added as sodium mercaptododecaborate (BSH). The results demonstrate that 11B but not 10B or other components of the BSH molecule enhance cell killing by proton beams. The enhancement occurs selectively in the Bragg peak region, is present for boron concentrations as low as 40 ppm, and is not due to secondary neutrons. The enhancement is likely initiated by proton-boron capture reactions producing three alpha particles, which are rare events occurring in a few cells only, and their effects are amplified by intercellular communication to a population-level response. The observed up to 2-3-fold reductions in survival levels upon the presence of boron for the studied prostate cancer or glioblastoma cells suggest promising clinical applications for these tumour types.

• Klíčová slova
• Biological effectiveness, Cell survival, Proton radiotherapy, Proton-boron capture therapy, Sodium mercaptododecaborate (BSH),
• MeSH
• bor chemie   MeSH
• glioblastom radioterapie   farmakoterapie   MeSH
• lidé MeSH
• nádorové buněčné linie MeSH
• nádory prostaty radioterapie   farmakoterapie   MeSH
• protonová terapie * metody   MeSH
• protony MeSH
• terapie metodou neutronového záchytu (bor-10) * metody   MeSH
• viabilita buněk účinky léků   účinky záření   MeSH
• Check Tag
• lidé MeSH
• mužské pohlaví MeSH
• Publikační typ
• časopisecké články MeSH
• Názvy látek
• bor MeSH
• protony MeSH